Page last updated: 2024-12-07
cl 232468
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CL 232468: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 125982 |
| CHEMBL ID | 1979181 |
| SCHEMBL ID | 4885984 |
| MeSH ID | M0127955 |
Synonyms (23)
| Synonym |
|---|
| 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthraquinone |
| NCI60_015291 |
| nsc645017 |
| nsc-645017 |
| aead |
| 1,4-bis(2-aminoethylamino)-5,8-dihydroxyanthracene-9,10-dione |
| 96555-65-6 |
| unii-ozx2bs7rj6 |
| cl 232,468 |
| 9,10-anthracenedione, 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy- |
| cl 232468 |
| ozx2bs7rj6 , |
| 1,4-bis[(2-aminoethyl)amino]-5,8-dihydroxyanthracene-9,10-dione |
| SCHEMBL4885984 |
| 1,4-bis[(2-aminoethyl)amino]-5,8-dihydroxyanthraquinone |
| CLVFWRBVFBUDQU-UHFFFAOYSA-N |
| CHEMBL1979181 |
| DTXSID80242325 |
| 1,4-dihydroxy-5,8-bis-(2-amino-ethylamino)-anthracen-9,10-dione |
| 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy-9,10-anthracenedione |
| Q27453982 |
| 9,10-anthracenedione, 1,4-bis((2-aminoethyl)amino)-5,8-dihydroxy |
| AKOS040751208 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1656533 | Stabilization of dsBE12 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis relative to control | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656536 | Stabilization of dsBE17 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656521 | Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation by measuring adduct half life incubated for 12 hrs in presence of formaldehyde by phosphorimaging analysis | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656532 | Binding affinity to dsBE45 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656522 | Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation at 5 uM in presence of formaldehyde incubated for 12 hrs by phosphorimaging analysis relative to control | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656534 | Stabilization of dsBE15 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656537 | Stabilization of dsBE67 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis relative to control | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| AID1656524 | Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation at 1 uM to 24 uM incubated for 12 hrs in presence of formaldehyde by phosphorimaging analysis | 2020 | Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3 | Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||